Gland Pharma gets USFDA nod for generic breast cancer drug

Gland Pharma has received approval from the USFDA to market a generic medication for breast cancer treatment, Eribulin Mesylate Injection. It’s expected to be the first generic approval in the market, with sales of around USD 92 million in the US.